What is Putney?
Putney is dedicated to delivering high-quality, cost-effective generic medicines for pets. By ensuring a reliable supply of affordable drug options, the company empowers veterinarians to offer optimal treatment at competitive prices, thereby supporting pet owners in adhering to prescribed veterinary care. Putney's strategic investments in research and development are geared towards innovating the next generation of generic veterinary products, informed by insights from companion animal veterinarians and industry collaborators. The company's focus on the veterinary pharmaceutical market positions it as a key player in making advanced pet care more attainable.
How much funding has Putney raised?
Putney has raised a total of $49.3M across 5 funding rounds:
Series A
$2.5M
Series B
$6.7M
Series C
$21M
Debt
$3M
Private Equity
$16.1M
Series A (2007): $2.5M, investors not publicly disclosed
Series B (2009): $6.7M, investors not publicly disclosed
Series C (2011): $21M supported by Safeguard Scientifics and NewSpring Capital
Debt (2014): $3M featuring NewSpring Health Capital
Private Equity (2014): $16.1M, investors not publicly disclosed
Key Investors in Putney
Safeguard Scientifics
Safeguard Scientifics is a venture capital and private equity firm that invests in technology-driven businesses, particularly in healthcare and digital media. They provide capital and expertise to foster growth.
NewSpring Capital
NewSpring Capital is a private equity firm that partners with management teams to develop businesses into market leaders. They focus on catalyzing growth across dynamic industries.
NewSpring Health Capital
NewSpring Health Capital, an arm of NewSpring Capital, likely focuses on investments within the healthcare and life sciences sectors, providing strategic backing for companies in this domain.
What's next for Putney?
With its recent major strategic investment, Putney is poised to accelerate its research and development initiatives and expand its product pipeline. The company's enterprise-level funding context suggests a strategic push towards scaling operations and potentially entering new market segments within the veterinary pharmaceutical space. Future endeavors will likely concentrate on leveraging its expertise in generic drug development to address unmet needs in animal health, further solidifying its role as a provider of accessible and high-quality veterinary pharmaceuticals. This strategic financing will be instrumental in achieving these ambitious goals.
See full Putney company page
